Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rodeo Therapeutics

- PMLiVE

NICE swayed by extra data on Amgen’s Imlygic

Cost effectiveness watchdog backs immunotherapy in final draft guidance

- PMLiVE

Amgen enters into $540m immunotherapy collaboration

Acquires global rights to Advaxis’ preclinical oncology candidate ADXS-NEO

- PMLiVE

Novartis gets FDA panel backing for biosimilar Enbrel

However Amgen claims patent protection for the psoriatic arthritis therapy is valid until 2029

- PMLiVE

Amgen’s Humira biosimilar moves closer to US approval

FDA committee backs company's version of AbbVie's blockbuster

Sanofi reception

Medivation softens on Sanofi takeover and opens its books

Due diligence agreement follows similar deals with Pfizer and Celgene

- PMLiVE

Pfizer set to snap up Bind’s assets for $20m

Biotech approves 'stalking horse' bid from the pharma giant

- PMLiVE

Amgen’s Kyprolis wins new indication in Europe

Regulators have handed the treatment a less restrictive licence in multiple myeloma 

- PMLiVE

Takeda hands back rights to two Amgen drugs

Returns pain and ovarian cancer candidates but will continue with collaboration

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

- PMLiVE

Amgen promotes Esteban Santos

He succeeds Madhavan Balachandran as executive vice president of operations

- PMLiVE

SMC rejects Amgen’s Repatha over lack of outcomes data

But gives GlaxoSmithKline’s asthma drug Nucala the green light

- PMLiVE

SMC approves Amgen orphan drug for use in NHS Scotland

Also accepts AbbVie's former orphan drug Duodopa, but rejects Sanofi's Jevtana

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links